Drugs / [68Ga]Ga-DOTA-CAIX peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07301827 | Jun 2025 → May 2026 overdue | renal cell carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-DOTA-CAIX peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07301827 ↗ |
| Modality | Peptide | “CAIX peptide” NCT07301827 ↗ |